PL3789389T3 - Postać krystaliczna (s)-n-[5-[1-(3-etoksy-4-metoksyfenylo)-2-(metylosulfonylo)etylo]-4,6-diokso-5,6-dihydro-4h-tieno[3,4-c]pirol-1-ilo]acetamidu - Google Patents

Postać krystaliczna (s)-n-[5-[1-(3-etoksy-4-metoksyfenylo)-2-(metylosulfonylo)etylo]-4,6-diokso-5,6-dihydro-4h-tieno[3,4-c]pirol-1-ilo]acetamidu

Info

Publication number
PL3789389T3
PL3789389T3 PL19797143.5T PL19797143T PL3789389T3 PL 3789389 T3 PL3789389 T3 PL 3789389T3 PL 19797143 T PL19797143 T PL 19797143T PL 3789389 T3 PL3789389 T3 PL 3789389T3
Authority
PL
Poland
Prior art keywords
pyrol
thieno
dioxo
methylsulfonyl
acetamide
Prior art date
Application number
PL19797143.5T
Other languages
English (en)
Polish (pl)
Inventor
Donglei ZHANG
Liyu WANG
Yukun CHANG
Original Assignee
Tianjin Hemay Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tianjin Hemay Pharmaceutical Co., Ltd. filed Critical Tianjin Hemay Pharmaceutical Co., Ltd.
Publication of PL3789389T3 publication Critical patent/PL3789389T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
PL19797143.5T 2018-05-02 2019-04-30 Postać krystaliczna (s)-n-[5-[1-(3-etoksy-4-metoksyfenylo)-2-(metylosulfonylo)etylo]-4,6-diokso-5,6-dihydro-4h-tieno[3,4-c]pirol-1-ilo]acetamidu PL3789389T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201810407741 2018-05-02
PCT/CN2019/085327 WO2019210864A1 (zh) 2018-05-02 2019-04-30 噻吩衍生物的晶型

Publications (1)

Publication Number Publication Date
PL3789389T3 true PL3789389T3 (pl) 2026-03-16

Family

ID=68386284

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19797143.5T PL3789389T3 (pl) 2018-05-02 2019-04-30 Postać krystaliczna (s)-n-[5-[1-(3-etoksy-4-metoksyfenylo)-2-(metylosulfonylo)etylo]-4,6-diokso-5,6-dihydro-4h-tieno[3,4-c]pirol-1-ilo]acetamidu

Country Status (14)

Country Link
US (4) US11396518B2 (enExample)
EP (5) EP3800190A4 (enExample)
JP (5) JP7481263B2 (enExample)
KR (4) KR102686835B1 (enExample)
CN (7) CN116947878B (enExample)
AU (4) AU2019262282B2 (enExample)
BR (4) BR112020021976A2 (enExample)
CA (4) CA3213055A1 (enExample)
DK (1) DK3789389T3 (enExample)
ES (1) ES3047059T3 (enExample)
FI (1) FI3789389T3 (enExample)
PL (1) PL3789389T3 (enExample)
PT (1) PT3789389T (enExample)
WO (4) WO2019210869A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3789389T3 (pl) * 2018-05-02 2026-03-16 Tianjin Hemay Pharmaceutical Co., Ltd. Postać krystaliczna (s)-n-[5-[1-(3-etoksy-4-metoksyfenylo)-2-(metylosulfonylo)etylo]-4,6-diokso-5,6-dihydro-4h-tieno[3,4-c]pirol-1-ilo]acetamidu
WO2025103428A1 (zh) * 2023-11-14 2025-05-22 赣州和美药业股份有限公司 中重度斑块型银屑病的治疗

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020358A (en) 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
AU2003243153A1 (en) * 2002-04-23 2003-11-10 Dr. Reddy's Laboratories Limited Novel crystalline polymorph form-vi of olanzapine and a process for preparation thereof
CN101186612B (zh) 2006-11-15 2012-10-03 天津和美生物技术有限公司 可抑制细胞释放肿瘤坏死因子的吡咯啉衍生物及其制备和应用
KR101514866B1 (ko) 2009-05-14 2015-04-24 티안진 헤메이 바이오-텍 컴퍼니 리미티드 티오펜 유도체
US8946474B2 (en) * 2010-06-30 2015-02-03 Leo Pharma A/S Polymorphic form of a calcimimetic compound
CN105793251B (zh) * 2013-12-05 2018-10-12 豪夫迈·罗氏有限公司 具有亲电子官能性的杂芳基吡啶酮和氮杂-吡啶酮化合物
WO2016010178A1 (ko) * 2014-07-18 2016-01-21 주식회사 녹십자 5-클로로-ｎ-({(5ｓ)-2-옥소-3-[4-(5,6-디하이드로-4h-[1,2,4]트리아진-1-일)페닐]-1,3-옥사졸리딘-5-일}메틸)티오펜-2-카르복사미드 메탄설폰산염의 신규 결정형 및 이를 포함하는 약학 조성물
EP3144393A1 (en) * 2015-09-18 2017-03-22 LEK Pharmaceuticals d.d. A synthetic pathway towards apremilast
CN107417626B (zh) * 2016-05-23 2020-01-24 江苏奥赛康药业有限公司 一种2-氨基嘧啶类化合物的多晶型形式
CN107474057B (zh) * 2016-06-07 2021-03-12 天津药物研究院有限公司 (5-(2-腈基苄基)-4,5,6,7-四氢噻吩并[3,2-c]吡啶-2-基)乙酸酯盐酸盐的晶型及其制备方法和用途
US10570147B2 (en) * 2017-06-13 2020-02-25 Biotheryx, Inc. Bicyclic compounds and methods of use
EP3644860B1 (en) * 2017-06-30 2024-05-08 Trophy An extra oral dental imaging apparatus with patient positioning accessory detection
PL3789389T3 (pl) 2018-05-02 2026-03-16 Tianjin Hemay Pharmaceutical Co., Ltd. Postać krystaliczna (s)-n-[5-[1-(3-etoksy-4-metoksyfenylo)-2-(metylosulfonylo)etylo]-4,6-diokso-5,6-dihydro-4h-tieno[3,4-c]pirol-1-ilo]acetamidu

Also Published As

Publication number Publication date
EP4335515A2 (en) 2024-03-13
US11396518B2 (en) 2022-07-26
DK3789389T3 (da) 2025-11-10
AU2019263865B2 (en) 2022-01-27
JP2024026251A (ja) 2024-02-28
FI3789389T3 (fi) 2025-11-19
JP2021523935A (ja) 2021-09-09
JP2021523891A (ja) 2021-09-09
KR20210025001A (ko) 2021-03-08
EP3789388B1 (en) 2024-01-24
JP7542523B2 (ja) 2024-08-30
AU2019262282A1 (en) 2020-11-12
EP3800190A4 (en) 2022-01-26
KR20210022557A (ko) 2021-03-03
CA3098927C (en) 2023-10-03
PT3789389T (pt) 2025-12-17
CA3099072A1 (en) 2019-11-07
KR102701245B1 (ko) 2024-08-30
EP3789387B1 (en) 2024-02-28
WO2019210864A1 (zh) 2019-11-07
ES3047059T3 (en) 2025-12-03
JP2021523890A (ja) 2021-09-09
BR112020022190A2 (pt) 2021-02-02
EP3789389A4 (en) 2022-01-26
EP3800190A1 (en) 2021-04-07
CN110437251B (zh) 2023-07-21
US12180222B2 (en) 2024-12-31
CN116854705A (zh) 2023-10-10
CA3098931C (en) 2023-10-24
EP3789389A1 (en) 2021-03-10
CA3099071A1 (en) 2019-11-07
US20210380600A1 (en) 2021-12-09
US20210139498A1 (en) 2021-05-13
CN116836178A (zh) 2023-10-03
EP3789387A4 (en) 2021-06-30
BR112020021945A2 (pt) 2021-01-26
WO2019210869A1 (zh) 2019-11-07
BR112020021976A2 (pt) 2021-01-26
JP7481263B2 (ja) 2024-05-10
US12227514B2 (en) 2025-02-18
WO2019210865A1 (zh) 2019-11-07
EP4335515A3 (en) 2024-07-03
JP7477459B2 (ja) 2024-05-01
KR20210022556A (ko) 2021-03-03
AU2019262286B2 (en) 2022-08-11
JP2021522348A (ja) 2021-08-30
US20210230181A1 (en) 2021-07-29
EP3789388A4 (en) 2021-06-09
CA3098931A1 (en) 2019-11-07
WO2019210867A1 (zh) 2019-11-07
AU2019263865A1 (en) 2020-12-24
CN110437250B (zh) 2023-06-23
CN110437249B (zh) 2023-07-21
US20210238191A1 (en) 2021-08-05
CN116947878A (zh) 2023-10-27
CN116854705B (zh) 2026-06-19
CN116947878B (zh) 2026-06-19
KR20210025000A (ko) 2021-03-08
EP3789388A1 (en) 2021-03-10
US11274104B2 (en) 2022-03-15
EP3789389B1 (en) 2025-10-08
CN116813637A (zh) 2023-09-29
CN110437251A (zh) 2019-11-12
AU2019262282B2 (en) 2022-04-28
AU2019262284A1 (en) 2020-12-24
CA3098927A1 (en) 2019-11-07
KR102839924B1 (ko) 2025-07-29
EP3789387A1 (en) 2021-03-10
CN110437250A (zh) 2019-11-12
CA3213055A1 (en) 2019-11-07
CN110437249A (zh) 2019-11-12
KR102686835B1 (ko) 2024-07-22
BR112020022186A2 (pt) 2021-02-02
AU2019262286A1 (en) 2020-11-12

Similar Documents

Publication Publication Date Title
EP3903206A4 (en) HASHING-BASED EFFECTIVE USER MODELING
IL282468A (en) 2- amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors
IL282698A (en) Gel and crystalline powder
EP3767709A4 (en) POSITIVE ELECTRODE COMPOSITION FOR LITHIUM ION SECONDARY CELL, POSITIVE ELECTRODE FOR LITHIUM ION SECONDARY CELL, and LITHIUM ION SECONDARY CELL
EP3769480A4 (en) HIERARCHICAL BIT-INDEXED REPLICATION OF MULTICAST PACKAGES
EP3769479A4 (en) HIERARCHICAL BIT-INDEXED REPLICATION OF MULTICAST PACKAGES
EP3769477A4 (en) HIERARCHICAL BIT-INDEXED REPLICATION OF MULTICAST PACKAGES
WO2017058603A3 (en) Compressible adjunct with attachment regions
EP3768854A4 (en) HSD17B13 EXPRESSION MODULATORS
MX2018005694A (es) 2- (1h-indazol-3-il) -3h-imidazo[4,5-c] piridinas y usos antiinflamatorios de las mismas.
EP3768267A4 (en) KINA INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE
CY1126466T1 (el) Παραγωγα φαινυλιου/πυριδυλ-νη-φαινυλιου/ πυριδυλιου για τη θεραπευτικη αντιμετωπιση ιικωνλοιμωξεων
EP3799602A4 (en) COMPOUNDS AND METHODS FOR REDUCING ATXN3 EXPRESSION
IL289456A (en) Eif4e-inhibiting 4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine compounds
MA48942A (fr) Composés thérapeutiques, compositions et procédés d'utilisation associés
PL3972643T3 (pl) Antagoniści układu dopełniacza do stosowania w sposobach leczenia neuropatii paraproteinemicznych
DK3986920T3 (da) Tnfr2-agonister med forbedret stabilitet
EP3959627A4 (en) MITIGATING THE RISK OF PHISHING
PT3908584T (pt) Formas cristalinas de 1-(1,2-dimetilpropil)-n-etil-5- metil-n-piridazin-4-il-pirazol-4-carboxamida
EP3906028A4 (en) KINA INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE
EP3851099C0 (en) COMPOSITION INTENDED FOR THE TREATMENT OF FIBROTIC DISEASES, COMPRISING BENZHYDRYL THIOACETAMIDE AS THE ACTIVE INGREDIENT
EP3819299A4 (en) HYPOXANTHINE COMPOUND
HUE059604T2 (hu) Eljárás 5-[[4-[2-[5-(1-hidroxietil)-2-piridinil]etoxi]fenil]metil]-2,4-tiazolidindion és sói elõállítására
DK3789389T3 (da) Krystallinsk form af (s)-n-[5-[1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-4,6-dioxo-5,6-dihydro-4h-thieno[3,4-c]pyrrol-1-yl]acetamid
EP3927155A4 (en) FISHING LURE, MOLDABLE COMPOSITION FOR MAKING THE FISHING LURE, METHOD OF MAKING THE FISHING LURE AND USE OF THE MOLDABLE COMPOSITION